Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue guidance of $2.06 billion at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.74 per share was 24.5% below analysts’ consensus estimates.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Tech stocks staged a full rebound from last Friday's sell-off, with the Nasdaq 100 surging to 23,600 — just shy of the 23,700 all-time high set in late July, as the week’s strong sector earnings and broad gains among the Magnificent Seven fueled the rally.
Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 11.6% in the morning session after it reported strong second-quarter 2025 financial results, including a significant revenue beat and raised full-year guidance. The company posted revenue of $546.6 million, up 32.2% year-over-year and surpassing Wall Street's estimates by a notable 14.7%. This growth was supported by a 12.7% increase in the number of tests processed. However, it was not all positive, as Natera's GAAP loss per share of $0.74 came in wider than analysts had expected. Despite the earnings miss, investors were encouraged by the company's upgraded forecast. Natera lifted its full-year revenue guidance to a midpoint of $2.06 billion, an $80 million increase from its previous projection, signaling confidence in its continued growth trajectory.
Genetic testing company Natera (NASDAQ:NTRA). reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 32.2% year on year to $546.6 million. The company’s full-year revenue guidance of $2.06 billion at the midpoint came in 4.2% above analysts’ estimates. Its GAAP loss of $0.74 per share was 19.3% below analysts’ consensus estimates.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%.
